Health Trials

Microsatellite Stable Colorectal Cancer

3

Review clinical trials related to Microsatellite Stable Colorectal Cancer. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.

Participants needed: 1,109
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Bristol-Myers SquibbUpdated: Jun 30, 2026Locations: 47
Eligibility criteria

Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker... [+5]

Women who are pregnant or breastfeeding. [+11]

Read more
Status: Recruiting

FOG-001 in Locally Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.

Participants needed: 595
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Parabilis Medicines, Inc.Updated: May 28, 2026Locations: 33
Eligibility criteria

Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. [+16]

Known history of bone metastasis. Bone metastasis are allowed for patients with... [+6]

Read more
Status: Recruiting

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).

Participants needed: 60
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: KaliVir ImmunotherapeuticsUpdated: Apr 7, 2026Locations: 7
Eligibility criteria

Have pathologically confirmed, advanced, unresectable, or metastatic solid tumor... [+6]

Prior systemic therapy washout (dependent upon the therapy) [+5]

Read more